Technical Analysis for RGNX - REGENXBIO Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| NR7 | Range Contraction | 0.82% | |
| Narrow Range Bar | Range Contraction | 0.82% | |
| Inside Day | Range Contraction | 0.82% | |
| Multiple of Ten Bullish | Other | -1.15% | |
| Up 3 Days in a Row | Strength | -1.15% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.56% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.56% | |
| Inside Day | Range Contraction | 0.56% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 23 hours ago |
| Up 2% | about 23 hours ago |
| Up 1% | about 24 hours ago |
| Possible NR7 | 2 days ago |
| Possible Inside Day | 2 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/08/2023
REGENXBIO Inc. Description
REGENXBIO Inc., a biotechnology company, focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company's development programs include RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate for the treatment of Mucopolysaccharidosis Type I, which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system. Its programs also include RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II; RGX-314, a product candidate for the treatment of wet age-related macular degeneration; and RGX-321, a product candidate for the treatment of X-linked retinitis pigmentosa. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Emerging Technologies Molecular Biology Gene Therapy Genetics Medical Genetics Macular Degeneration Applied Genetics Cholesterol Gene Delivery Wet Age Related Macular Degeneration Lipoprotein Hypercholesterolemia Retinitis Adeno Associated Virus Mucopolysaccharidosis Retinitis Pigmentosa Homozygous Familial Hypercholesterolemia Iduronidase Rgx
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 25.54 |
| 52 Week Low | 12.82 |
| Average Volume | 455,211 |
| 200-Day Moving Average | 18.65 |
| 50-Day Moving Average | 17.06 |
| 20-Day Moving Average | 18.98 |
| 10-Day Moving Average | 19.43 |
| Average True Range | 0.86 |
| RSI (14) | 61.83 |
| ADX | 34.63 |
| +DI | 29.15 |
| -DI | 11.42 |
| Chandelier Exit (Long, 3 ATRs) | 18.29 |
| Chandelier Exit (Short, 3 ATRs) | 17.59 |
| Upper Bollinger Bands | 20.97 |
| Lower Bollinger Band | 16.99 |
| Percent B (%b) | 0.7 |
| BandWidth | 20.98 |
| MACD Line | 0.83 |
| MACD Signal Line | 0.83 |
| MACD Histogram | -0.0048 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 20.57 | ||||
| Resistance 3 (R3) | 20.60 | 20.37 | 20.44 | ||
| Resistance 2 (R2) | 20.37 | 20.17 | 20.35 | 20.39 | |
| Resistance 1 (R1) | 20.07 | 20.04 | 19.96 | 20.04 | 20.35 |
| Pivot Point | 19.84 | 19.84 | 19.78 | 19.83 | 19.84 |
| Support 1 (S1) | 19.55 | 19.64 | 19.43 | 19.52 | 19.21 |
| Support 2 (S2) | 19.32 | 19.52 | 19.30 | 19.17 | |
| Support 3 (S3) | 19.02 | 19.32 | 19.12 | ||
| Support 4 (S4) | 18.99 |
